Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denagliptin in Type 2 Diabetes
NCT00387972Phase 3Withdrawn
- Sponsor
- GSK
- Start
- May 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in blood glucose regulation at 26 weeks. Planned start May 2006; status: withdrawn.
02
Drugs
denagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00387972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387972.